Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-titration study of nevanimibe hydrochloride in adults with classic congenital adrenal hyperplasia
MOH_2018-11-05_002360Phase 2Completed
- Sponsor
- Millendo Therapeutics
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Nevanimibe in congenital adrenal hyperplasia (CAH), sponsored by Millendo Therapeutics. Primary endpoint: Not reported. Started Jun 2018; status: completed.
02
Drugs
Nevanimibe
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on MOH_2018-11-05_002360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-05_002360.